Clinical trials: Rosuvastatin
Hyperlipidemia
A Clinical Trial of HRS-1301 on the Pharmacokinetics of Rosuvastatin Calcium Tablets in Healthy Subjects
The study was designed to evaluate the pharmacokinetic effects of rosuvastatin calcium tablets after oral administration of HRS-1301 in healthy subjects.
- Trial name
- NCT07097831
- Testing
- HRS-1301 Tablets, Rosuvastatin Calcium Tablets
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Autoimmune Diseases, Inflammatory Diseases
Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin
The study is to assess the effect of coadministration of multiple doses of BMS-986165 on the systemic exposure of rosuvastatin in healthy participants.
- Trial name
- NCT03044873
- Testing
- BMS-986165, Rosuvastatin
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy Volunteers
Investigation of the Gut Microbiome and Statin Response
There is evidence that the bacteria that naturally reside in the gut can influence how well we respond to medications. Therefore this study will look at how rosuvastatin, a medication used to lower cholesterol levels, may change…
- Trial name
- INGEST (NCT04098003)
- Testing
- Rosuvastatin
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Sony Tuteja
Healthy Individuals
Bioequivalence Study of Rosuvastatin Tablet
This study is designed to explore the bioequivalence of Test Product Vaptor (Rosuvastatin) 20 mg Tablet with the reference product Crestor (Rosuvastatin) 20 mg tablet under fasting conditions in healthy Pakistani male subjects.
- Trial name
- BE (NCT05637060)
- Testing
- Test Drug, Reference Drug
- Where
- Pakistan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Karachi
Dyslipidemias, Hypertension
To Evaluate the Pharmacokinetics and the Safety of ID14009 Compared to Coadministration of ID1805 With ID1803 in Healthy Adult Volunteers
To evaluate the pharmacokinetics and the safety of ID14009 compared to coadministration of ID1805 with ID1803 in healthy adult volunteers.
- Trial name
- NCT05259020
- Testing
- ID140009, ID1803+ID1805
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- IlDong Pharmaceutical Co Ltd
Healthy Male Volunteers
A Study in Healthy Male Participants to Compare How CHF10196 Affects How the Body Absorbs and Processes Two Commonly Used Medicines: Dabigatran, a Blood Thinner, and Rosuvastatin, a Medicine Used to Lower Cholesterol
The purpose of this study is to assess the potential drug-drug interaction of CHF10196 (a dipeptidyl peptidase 1 inhibitor) and its metabolite on the pharmacokinetics of dabigatran (a P-glycoprotein substrate) and Rosuvastatin (a…
- Trial name
- NCT07744386
- Testing
- Dabigatran Etexilate, Rosuvastatin, CHF10196
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Ischemic Stroke
Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Small Vessel Stroke
Along with the current clinical trial, the impact of adding atorvastatin or rosuvastatin in the first 24 hours on the clinical outcomes of first-ever small vessel stroke patients treated with clopidogrel and aspirin assessed…
- Trial name
- NCT06358313
- Testing
- Atorvastatin 40mg, Rosuvastatin 20mg
- Where
- Egypt
- Volunteers
- 600 people
- Sponsor
- Kafrelsheikh University
Healthy Volunteer Study
Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998)
Drug-drug interaction study of rosuvastatin and AT-527 (R07496998)
- Trial name
- NCT05154123
- Testing
- Drug: AT-527 + rosuvastatin, AT-527 + rosuvastatin
- Where
- Canada
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Atea Pharmaceuticals, Inc.
Hypercholesterolaemia
OLE Study to Evaluate Safety / Efficacy of ZD4522
The purpose of this study is to assess the long term safety of Crestor.
- Trial name
- NCT00654303
- Testing
- Rosuvastatin
- Volunteers
- 3,500 people
- Sponsor
- AstraZeneca
Coronary Heart Disease
Assessment of the Lipid Lowering Effect of Rosuvastatin Compared to Atorvastatin in Subjects With Coronary Heart Disease
The purpose of this study is to compare the efficacy between two lipid lowering treatments, rosuvastatin (10-40 mg) and atorvastatin (20-80 mg) in reducing low-density lipoprotein cholesterol (LDL-C) levels after 16 weeks of…
- Trial name
- NCT00235950
- Testing
- Rosuvastatin or atorvastatin or simvastatin and clopidogrel
- Where
- 18 sites in Sweden
- Volunteers
- 255 people
- Sponsor
- AstraZeneca
Obstructive Coronary Artery Disease, Coronary Artery Disease
YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering
Coronary artery disease (CAD) remains a leading cause of death in most countries. It is well known that the reduction of cholesterol levels by statin therapy is associated with significant decreases in plaque burden.
- Trial name
- NCT01837823
- Testing
- rosuvastatin
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Osteoporosis
A Study Of SB-751689, Atorvastatin, Ketoconazole, And Rosuvastatin In Health Postmenopausal Women.
The first purpose of this study is to determine if taking SB-751689 along with Rosuvastatin (CRESTOR) or Atorvastatin (LIPITOR) will change how Rosuvastatin or Atorvastatin are absorbed and eliminated from the body.
- Trial name
- NCT00388596
- Testing
- SB-751689
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections
VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)
This study will assess safety, tolerability and pharmacokinetic (PK) of VH3739937 in healthy participants.
- Trial name
- NCT06533280
- Testing
- Part A, C and D: VH3739937 500 mg, Part A: VH3739937 100 mg, Part B: Treatment A
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Dyslipidemia
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects
This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD0780 following single and multiple dose administration to healthy subjects with or without elevated Low-Density…
- Trial name
- NCT05384262
- Testing
- AZD0780, Rosuvastatin
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hypertension, Dyslipidemias
A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia
A Randomized, Double-blinded, Multi-center, Phase III Study to Compare The Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 versus HCP1701 in Patients with Hypertension and Dyslipidemia
- Trial name
- NCT04074551
- Testing
- HCP1701, Losartan, Amlodipine
- Where
- South Korea
- Volunteers
- 145 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Stroke, Transient Ischemic Attack
Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives
Stroke is one of the major causes not only of mortality, but of disease burden worldwide, because of residual disability and cognitive decline.
- Conditions
- Stroke, Transient Ischemic Attack, Hypertension
- Trial name
- ESH-CHL-SHOT (NCT01563731)
- Testing
- all approved antihypertensive drugs; all approved statins
- Where
- Russia
- Volunteers
- 200 people
- Sponsor
- Istituto Auxologico Italiano
Coronary Artery Disease
PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in Acute Coronary Syndromes (REPRESS)
In this prospective, multicenter, open-label trial, 212 ACS patients will be randomized 1:1 to either the "PCSK9i early" intensified therapy group (initial addition of PCSK9i to moderate-intensity statin) or the…
- Trial name
- NCT06791031
- Testing
- PCSK9 inhibitor (PCSK9i)
- Volunteers
- 212 people
- Sponsor
- West China Hospital
Hypercholesterolemia, Dyslipidemia
A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins
PF-04950615 is a new investigational hypercholesterolemic agent that is being tested in this study to evaluate if it can lower LDL cholesterol.
- Trial name
- NCT01350141
- Testing
- PF-04950615 (RN316)
- Where
- 35 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- Pfizer
Hyperlipidemia, Atherosclerosis
Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH)
This study is to evaluate the effect of rosuvastatin 10-20 mg on carotid atherosclerosis progression in Chinese patients by evaluating the change in the percentage of volume of lipid rich necrotic core (LRNC) using…
- Trial name
- REACH (NCT00885872)
- Testing
- Rosuvastatin (Crestor)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chinese PLA General Hospital
Acute Coronary Syndromes
LUNAR IIIb Study Comparing Rosuvastatin and Atorvastatin in Subjects With Acute Coronary Syndromes
Comparison of rosuvastatin and atorvastatin in subjects with acute coronary syndromes
- Trial name
- NCT00214630
- Testing
- rosuvastatin calcium, atorvastatin
- Where
- 56 sites in United States, Costa Rica and 3 more
- Volunteers
- 825 people
- Sponsor
- AstraZeneca